Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Mitochondrial isocitrate dehydrogenase impedes CAR T cell function by restraining antioxidant metabolism and histone acetylation
Xiaohui Si, Mi Shao, Xinyi Teng, et al.
Cell Metabolism (2024) Vol. 36, Iss. 1, pp. 176-192.e10
Closed Access | Times Cited: 30

Showing 1-25 of 30 citing articles:

Inhibition of CD38 enzymatic activity enhances CAR-T cell immune-therapeutic efficacy by repressing glycolytic metabolism
Yue Huang, Mi Shao, Xinyi Teng, et al.
Cell Reports Medicine (2024) Vol. 5, Iss. 2, pp. 101400-101400
Open Access | Times Cited: 19
T cell dysfunction and therapeutic intervention in cancer
Caitlin C. Zebley, Dietmar Zehn, Stephen Gottschalk, et al.
Nature Immunology (2024) Vol. 25, Iss. 8, pp. 1344-1354
Closed Access | Times Cited: 18
Class I HDAC inhibitors enhance antitumor efficacy and persistence of CAR-T cells by activation of the Wnt pathway
Meng Zhu, Yingli Han, Tianning Gu, et al.
Cell Reports (2024) Vol. 43, Iss. 4, pp. 114065-114065
Closed Access | Times Cited: 16
Immunometabolism of CD8+ T cell differentiation in cancer
Hao Shi, Sidi Chen, Hongbo Chi
Trends in cancer (2024) Vol. 10, Iss. 7, pp. 610-626
Closed Access | Times Cited: 15
Tumor-induced metabolic immunosuppression: Mechanisms and therapeutic targets
Jean‐Ehrland Ricci
Cell Reports (2025) Vol. 44, Iss. 1, pp. 115206-115206
Closed Access | Times Cited: 2
Future perspectives on engineered T cells for cancer
Avery D. Posey, Regina M. Young, Carl H. June
Trends in cancer (2024) Vol. 10, Iss. 8, pp. 687-695
Open Access | Times Cited: 12
MEK inhibition prevents CAR-T cell exhaustion and differentiation via downregulation of c-Fos and JunB
Xiu‐Jian Wang, Tao Xiao, Pengjie Chen, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 6
Nature’s magic: how natural products work hand in hand with mitochondria to treat stroke
Lin Cheng, Shangbin Lv, Wei Chen, et al.
Frontiers in Pharmacology (2025) Vol. 15
Open Access
The Pentose Phosphate Pathway: From Mechanisms to Implications for Gastrointestinal Cancers
Jincheng Qiao, Zhiqing Yu, Han Zhou, et al.
International Journal of Molecular Sciences (2025) Vol. 26, Iss. 2, pp. 610-610
Open Access
Bridging epigenomics and tumor immunometabolism: molecular mechanisms and therapeutic implications
Xiaowen Xie, Weici Liu, Zhiyuan Yuan, et al.
Molecular Cancer (2025) Vol. 24, Iss. 1
Open Access
Sodium citrate pretreatment enhances CAR-T cell persistence and anti-tumor efficacy through inhibition of calcium signaling
Xuechen Yin, Wenwen Chen, Xudong Ao, et al.
Frontiers in Immunology (2025) Vol. 16
Open Access
New insights into T cell metabolism in liver cancer: from mechanism to therapy
Jie Xiao, Ting Liu, Fanxin Zeng, et al.
Cell Death Discovery (2025) Vol. 11, Iss. 1
Open Access
Metabolic reprogram and T cell differentiation in inflammation: current evidence and future perspectives
Yuxin Shi, Hao Zhang, Changhong Miao
Cell Death Discovery (2025) Vol. 11, Iss. 1
Open Access
Targeting P4HA1 promotes CD8+ T cell progenitor expansion toward immune memory and systemic anti-tumor immunity
Shijun Ma, L.S. Ong, Zemin Jiang, et al.
Cancer Cell (2024)
Closed Access | Times Cited: 4
Fueling CARs: metabolic strategies to enhance CAR T-cell therapy
Arne Van der Vreken, Karin Vanderkerken, Elke De Bruyne, et al.
Experimental Hematology and Oncology (2024) Vol. 13, Iss. 1
Open Access | Times Cited: 3
Targeting metabolism to improve CAR-T cells therapeutic efficacy
Shasha Liu, Yuyu Zhao, Yaoxin Gao, et al.
Chinese Medical Journal (2024) Vol. 137, Iss. 8, pp. 909-920
Open Access | Times Cited: 2
Targeting mitochondria: restoring the antitumor efficacy of exhausted T cells
Meiqi Yang, Shuling Zhang, Li Sun, et al.
Molecular Cancer (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 2
Targeting metabolic dysfunction of CD8 T cells and natural killer cells in cancer
Sébastien Viel, Éric Vivier, Thierry Walzer, et al.
Nature Reviews Drug Discovery (2024)
Closed Access | Times Cited: 2
Unraveling the roles and mechanisms of mitochondrial translation in normal and malignant hematopoiesis
Lianxuan Liu, Mi Shao, Yue Huang, et al.
Journal of Hematology & Oncology (2024) Vol. 17, Iss. 1
Open Access | Times Cited: 1
Optimizing CAR-T Cell Function in Solid Tumor Microenvironment: Insights from Culture Media Additives
Wenwen Chen, Lei Xu, Zhigang Guo, et al.
Current Research in Translational Medicine (2024) Vol. 73, Iss. 2, pp. 103491-103491
Closed Access | Times Cited: 1
Synthetic Cells and Molecules in Cellular Immunotherapy
Haikun Lin, Chentao Li, Wanying Zhang, et al.
International Journal of Biological Sciences (2024) Vol. 20, Iss. 8, pp. 2833-2859
Open Access | Times Cited: 1
Targeting metabolic pathway enhance CAR-T potency for solid tumor
Wenying Li, Jiannan Chen, Zhigang Guo
International Immunopharmacology (2024) Vol. 143, pp. 113412-113412
Closed Access | Times Cited: 1
Immunometabolism unveiled: Pioneering breakthroughs in cancer therapeutics
Eric Eldering, Jean‐Ehrland Ricci
Molecular Oncology (2024) Vol. 18, Iss. 7, pp. 1691-1694
Open Access
Crizotinib and its enantiomer suppress ferroptosis by decreasing PE-O-PUFA content
Si-Yu Cen, Fang Lin, Xuan Li, et al.
Cell Death Discovery (2024) Vol. 10, Iss. 1
Open Access
IDH2 Inhibitors Gain a Wildcard Status in the Cancer Therapeutics Competition
Roberto Piva, Nariman Gharari, María Labrador, et al.
Cancers (2024) Vol. 16, Iss. 19, pp. 3280-3280
Open Access
Page 1 - Next Page

Scroll to top